Reuters logo
BRIEF-Interim analysis from phase 3 open-label extension study of Soliris
September 13, 2017 / 10:08 PM / 6 days ago

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

Sept 13 (Reuters) - Alexion Pharmaceuticals Inc:

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

* Says safety profile of Soliris was consistent with that observed in REGAIN study

* Says ‍study is ongoing and planned to continue until January 2019​

* Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​

* Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales

* Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​

* Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below